Jerusalem, 8 July, 2025 (TPS-IL) — Israeli biotech firm Lutris Pharma reported strong Phase 2 trial results for its skin gel, LUT014, which treats rashes caused by common cancer drugs like cetuximab and panitumumab. The results, presented at the recent ESMO GI Cancers Congress in Barcelona, showed the gel significantly reduced acne-like rashes in patients with advanced colorectal cancer.

The trial included 118 patients, and the high-dose version of the gel outperformed a placebo. Developed in Israel, LUT014 could help cancer patients avoid reducing or stopping treatment due to painful skin side effects. Lutris aims to offer the first approved treatment for this common complication.